AbbVie Announces Acquisition of Capstan Therapeutics and Innovative In Vivo Technology

lab analysis diagnostics hospital test tube test tests medical the doctor test tubes medic treatment patient diagnostician health

AI-assisted, human-published

AbbVie reaches definitive agreement to acquire Capstan Therapeutics, including potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate and proprietary tLNP platform technology, aiming to advance treatments for autoimmune diseases and reset the immune system.

AbbVie and Capstan Therapeutics, Inc. have reached a definitive agreement for AbbVie to acquire Capstan, including its potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, CPTX2309, as well as Capstan's proprietary tLNP platform technology designed to deliver RNA payloads.

The acquisition aims to advance treatments for autoimmune diseases and reset the immune system. The agreement includes AbbVie paying up to $2.1 billion in cash at closing, subject to customary adjustments. Capstan's exclusive financial advisor was Centerview Partners LLC, with Cooley LLP serving as legal advisor.

AbbVie is focused on discovering and delivering innovative medicines across various therapeutic areas, while Capstan is dedicated to developing targeted in vivo RNA technologies, with a focus on in vivo CAR-T therapies for autoimmune diseases.